

Emily Tateyama  
Colorado State University Honors Program  
Fall 2024

1. Frank K. M. (2014). Microbiology in Clinical Pathology. *Pathobiology of Human Disease*, 3237–3268. <https://doi.org/10.1016/B978-0-12-386456-7.06304-8>
2. Davidson, M. W. (2015, November 13). *Bacteria Cell Structure*. Molecular expressions cell biology: Bacteria cell structure. <https://micro.magnet.fsu.edu/cells/bacteriacell.html>
3. Bailey, Regina. (2024, May 24). What Are Prokaryotic Cells? Retrieved from <https://www.thoughtco.com/prokaryotes-meaning-373369>
4. Britannica, T. Editors of Encyclopaedia (2021, September 22). virus summary. Encyclopedia Britannica. <https://www.britannica.com/summary/virus>
5. Manna, P. R., Gray, Z. C., & Reddy, P. H. (2022). Healthy immunity on preventive medicine for combating COVID-19. *Nutrients*, 14(5), 1004.
6. Gelderblom, H. R. (1996). Structure and Classification of Viruses. In S. Baron (Ed.), *Medical Microbiology*. (4th ed.). University of Texas Medical Branch at Galveston.
7. Ruiz-Saenz, J., & Rodas, J. D. (2010). Viruses, virophages, and their living nature. *Acta virologica*, 54(2), 85–90. [https://doi.org/10.4149/av\\_2010\\_02\\_85](https://doi.org/10.4149/av_2010_02_85)
8. Mahr, J. A., & Gooding, L. R. (1999). Immune evasion by adenoviruses. *Immunological reviews*, 168, 121–130. <https://doi.org/10.1111/j.1600-065x.1999.tb01287.x>
9. Steel, J., & Lowen, A. C. (2014). Influenza A virus reassortment. *Current topics in microbiology and immunology*, 385, 377–401. [https://doi.org/10.1007/82\\_2014\\_395](https://doi.org/10.1007/82_2014_395)
10. Louten J. (2016). Virus Replication. *Essential Human Virology*, 49–70. <https://doi.org/10.1016/B978-0-12-800947-5.00004-1>
11. Applewhite, A. (n.d.). *Meet your microbiome*. American Museum of Natural History. <https://www.amnh.org/explore/science-topics/microbiome-health/meet-your-microbiome>
12. Wencewicz T. A. (2019). Crossroads of Antibiotic Resistance and Biosynthesis. *Journal of molecular biology*, 431(18), 3370–3399. <https://doi.org/10.1016/j.jmb.2019.06.033>
13. Czepiel, J., Drózdź, M., Pituch, H., Kuijper, E. J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019). Clostridium difficile infection: review. *European journal of clinical microbiology & infectious*

- diseases : official publication of the European Society of Clinical Microbiology*, 38(7), 1211–1221. <https://doi.org/10.1007/s10096-019-03539-6>
14. Dempsey, P. W., Vaidya, S. A., & Cheng, G. (2003). The art of war: Innate and adaptive immune responses. *Cellular and molecular life sciences : CMLS*, 60(12), 2604–2621. <https://doi.org/10.1007/s00018-003-3180-y>
  15. Saville, M. (2021, September 6). *Comparator vaccines are needed if vital COVID-19 R&D is to progress*. CEPI. <https://cepi.net/comparator-vaccines-are-needed-if-vital-covid-19-rd-progress>
  16. Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023). Tracking the COVID-19 vaccines: The global landscape. *Human vaccines & immunotherapeutics*, 19(1), 2191577. <https://doi.org/10.1080/21645515.2023.2191577>
  17. Gingles, J. G., & Doyle, M. Q. (2023). Immunization. In *StatPearls*. StatPearls Publishing.
  18. *Covid-19 vaccine: What you need to know*. Johns Hopkins Medicine. (2024, September 27). <https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccine-what-you-need-to-know#:~:text=The%202024%E2%80%9325%20COVID%2D19,and%20there%20are%20no%20boosters.>
  19. Centers for Disease Control and Prevention. (2021, November 16). *Administering HPV Vaccine*. Centers for Disease Control and Prevention. <https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html#:~:text=HPV%20vaccination%20is%20administered%20as,years%2C%20and%20for%20immunocompromised%20persons.>
  20. *The Pros and cons of vaccinations: Risk of vaccine side effects or the risk of disease*. London Vaccination Clinic. (n.d.). <https://www.londonvaccinationclinic.co.uk/blog/pros-and-cons-of-vaccines-london-vaccination-clinic/>